EN | RU
EN | RU

Help Support

Back

Safety and effectiveness of Polaprezinc versus Rebamipide for gastric ulcer treatment

Polaprezinc versus Rebamipide Polaprezinc versus Rebamipide
Polaprezinc versus Rebamipide Polaprezinc versus Rebamipide

A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical study was carried out to determine efficacy and safety of Polaprezinc and Rebamipide in patients with stomach ulcers.

See All

Key take away

For the treatment of gastric ulcers, Polaprezinc has comparable effectiveness and safety to Rebamipide.

Background

A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical study was carried out to determine efficacy and safety of Polaprezinc and Rebamipide in patients with stomach ulcers.

Method

People suffering from gastric ulcers (n = 224) were prospectively recruited and split into test (n = 111) or control (n = 113) group at random. Subjects in the test group received Polaprezinc whereas the subjects in the control group were given Rebamipide tablets. Following eight weeks of therapy, a gastroscopy was used to confirm the primary outcome, which was the rate of efficient treatment. The rate of improvement in gastrointestinal (GI) symptoms after four and eight weeks of therapy served as the secondary efficacy outcome.

Result

The two groups' fundamental traits were well balanced. For the primary efficacy outcome, the effective rates following treatment in the test and control groups, as determined by gastroscopy are shown in Table 1. Both the study groups experienced a similar rate of improvement in GI symptoms after four and eight weeks of therapy.

Comparable adverse events and reactions to study medicines were observed across both groups.

Conclusion

Polaprezinc granules offer the same therapeutic impact on gastric ulcers as commonly prescribed medications in clinical settings.

Source:

Medical Engineering & Physics

Article:

Efficacy and safety of Polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial

Authors:

Wei Shen et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: